{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"medRxiv"}],"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T13:14:04Z","timestamp":1768569244201,"version":"3.49.0"},"posted":{"date-parts":[[2025,8,26]]},"group-title":"Health Policy","reference-count":36,"publisher":"openRxiv","license":[{"start":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T00:00:00Z","timestamp":1756166400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2025,8,26]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>With the rising misuse of benzodiazepine (BZD) and associated overdose deaths, cannabis has been touted as a potential substitute with proposed benefit of better health outcomes. This two-year retrospective analysis examined whether cannabis use among BZD users was associated with changes in outcomes of (1) all-cause mortality, (2) hospitalizations, (3) emergency department (ED) visits, and (4) whether it demonstrated BZD-sparing effects on prescription quantity over time.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Using data from Yale New Haven Health System, we conducted a retrospective, longitudinal cohort study among BZD users. Cannabis use was the primary exposure, with BZD users without cannabis exposure as controls. Using inverse probability of treatment weighting and propensity score matching techniques, cohorts were balanced at baseline adjusting for medical comorbidities, socioeconomic status and other clinical factors. Kaplan-Meier curves and Cox proportional hazard models were examined with four outcomes of interest.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The sample included 1,026 patients with 60.3% females and mean age was 54.2. There was no significant effect of cannabis use on BZD quantity. Cannabis use was not significantly associated with all-cause mortality, hospitalization, or ED visits. In exploratory analysis, medical cannabis users had a lower risk of all-cause mortality but greater risk for hospitalizations among those aged &lt; 50 years.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>In this longitudinal cohort study, cannabis use was not significantly associated with all-cause mortality, hospitalization and ED visits, or benzodiazepine dose reduction. Our results do not support a benzodiazepine-sparing effect for cannabis use.<\/jats:p>\n                <\/jats:sec>","DOI":"10.1101\/2025.08.23.25334295","type":"posted-content","created":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T23:40:13Z","timestamp":1756251613000},"source":"Crossref","is-referenced-by-count":0,"title":["Impact of cannabis use on health outcomes and prescription benzodiazepine use"],"prefix":"10.64898","author":[{"given":"Nirmal","family":"Singh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Dai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuel T.","family":"Wilkinson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taeho Greg","family":"Rhee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8220-655X","authenticated-orcid":false,"given":"Rajiv","family":"Radhakrishnan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"54368","reference":[{"issue":"6","key":"2025083000350614000_2025.08.23.25334295v1.1","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1080\/00952990.2019.1569668","article-title":"Time trends in US cannabis use and cannabis use disorders overall and by sociodemographic subgroups: a narrative review and new findings","volume":"45","year":"2019","journal-title":"The American journal of drug and alcohol abuse"},{"issue":"5","key":"2025083000350614000_2025.08.23.25334295v1.2","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1007\/s00213-021-06047-8","article-title":"Prevalence and self-reported reasons of cannabis use for medical purposes in USA and Canada","volume":"239","year":"2022","journal-title":"Psychopharmacology"},{"issue":"3","key":"2025083000350614000_2025.08.23.25334295v1.3","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.amepre.2023.03.005","article-title":"Increasing use of cannabis for medical purposes among US residents, 2013\u20132020","volume":"65","year":"2023","journal-title":"American journal of preventive medicine"},{"key":"2025083000350614000_2025.08.23.25334295v1.4","doi-asserted-by":"crossref","unstructured":"Patrick, M.E. , et al., Historical trends in cannabis use among US adults aged 19-55, 2013-2021. Journal of studies on alcohol and drugs, 2024: p. jsad. 23\u201300169.","DOI":"10.15288\/jsad.23-00169"},{"key":"2025083000350614000_2025.08.23.25334295v1.5","doi-asserted-by":"crossref","unstructured":"D\u2019Souza, D.C. , D. Castle , and R. Murray , Marijuana and madness. 2023: Cambridge University Press.","DOI":"10.1017\/9781108943246"},{"key":"2025083000350614000_2025.08.23.25334295v1.6","unstructured":"Kryskow, A.B ., The Use of Medical Cannabis in Clinical Practice. 2021: The University of Maine."},{"key":"2025083000350614000_2025.08.23.25334295v1.7","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ps.201800321"},{"key":"2025083000350614000_2025.08.23.25334295v1.8","doi-asserted-by":"crossref","unstructured":"Blanco, C. , et al., Prevalence and Correlates of Benzodiazepine Use, Misuse, and Use Disorders Among Adults in the United States. JOURNAL OF CLINICAL PSYCHIATRY, 2018. 79.","DOI":"10.4088\/JCP.18m12174"},{"key":"2025083000350614000_2025.08.23.25334295v1.9","unstructured":"Report, N.A.N. https:\/\/www.samhsa.gov\/data\/report\/2021-nsduh-annual-national-report."},{"key":"2025083000350614000_2025.08.23.25334295v1.10","unstructured":"NIDA. https:\/\/nida.nih.gov\/research-topics\/trends-statistics\/overdose-death-rates#Fig9. 2023."},{"key":"2025083000350614000_2025.08.23.25334295v1.11","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3988\/jcn.2019.15.1.9","article-title":"Risk of Dementia in Long-Term Benzodiazepine Users: Evidence from a Meta-Analysis of Observational Studies","volume":"15","year":"2019","journal-title":"JOURNAL OF CLINICAL NEUROLOGY"},{"key":"2025083000350614000_2025.08.23.25334295v1.12","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.amepre.2019.11.017","article-title":"Emergency Department Visits Attributed to Adverse Events Involving Benzodiazepines, 2016-2017","volume":"58","year":"2020","journal-title":"AMERICAN JOURNAL OF PREVENTIVE MEDICINE"},{"key":"2025083000350614000_2025.08.23.25334295v1.13","doi-asserted-by":"crossref","unstructured":"Seppala, L. , et al., Fall-Risk-Increasing Drugs: A Systematic Review and Meta-Analysis: II. Psychotropics. JOURNAL OF THE AMERICAN MEDICAL DIRECTORS ASSOCIATION, 2018. 19.","DOI":"10.1016\/j.jamda.2017.12.098"},{"key":"2025083000350614000_2025.08.23.25334295v1.14","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1988.00380110083017"},{"key":"2025083000350614000_2025.08.23.25334295v1.15","doi-asserted-by":"crossref","unstructured":"Patorno, E. , et al., Benzodiazepines and risk of all cause mortality in adults: cohort study. BMJ-BRITISH MEDICAL JOURNAL, 2017. 358.","DOI":"10.1136\/bmj.j2941"},{"issue":"6","key":"2025083000350614000_2025.08.23.25334295v1.16","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1177\/0004867415616695","article-title":"Mortality associated with anxiolytic and hypnotic drugs\u2014A systematic review and meta-analysis","volume":"50","year":"2016","journal-title":"Australian & New Zealand Journal of Psychiatry"},{"key":"2025083000350614000_2025.08.23.25334295v1.17","unstructured":"Day, C. , Benzodiazepines in combination with opioid pain relievers or alcohol: greater risk of more serious ED visit outcomes. 2016."},{"key":"2025083000350614000_2025.08.23.25334295v1.18","doi-asserted-by":"publisher","DOI":"10.1177\/0269881117699616"},{"key":"2025083000350614000_2025.08.23.25334295v1.19","first-page":"1","article-title":"Cannabis, a cause for anxiety? A critical appraisal of the anxiogenic and anxiolytic properties","volume":"18","year":"2020","journal-title":"Journal of translational medicine"},{"issue":"1","key":"2025083000350614000_2025.08.23.25334295v1.20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/YCO.0000000000000566","article-title":"The role of cannabis in treating anxiety: an update","volume":"33","year":"2020","journal-title":"Current Opinion in Psychiatry"},{"key":"2025083000350614000_2025.08.23.25334295v1.21","doi-asserted-by":"crossref","first-page":"989","DOI":"10.2147\/JPR.S134330","article-title":"Cannabis as a substitute for prescription drugs - a cross-sectional study","volume":"10","year":"2017","journal-title":"JOURNAL OF PAIN RESEARCH"},{"key":"2025083000350614000_2025.08.23.25334295v1.22","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1177\/1060028019854221","article-title":"Medical Cannabis: Effects on Opioid and Benzodiazepine Requirements for Pain Control","volume":"53","year":"2019","journal-title":"ANNALS OF PHARMACOTHERAPY"},{"key":"2025083000350614000_2025.08.23.25334295v1.23","unstructured":"Data, U.C.B.A.C.S., https:\/\/www.census.gov\/programs-surveys\/acs\/data.html."},{"key":"2025083000350614000_2025.08.23.25334295v1.24","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9681(87)90171-8"},{"key":"2025083000350614000_2025.08.23.25334295v1.25","doi-asserted-by":"publisher","DOI":"10.1111\/j.1467-6419.2007.00527.x"},{"key":"2025083000350614000_2025.08.23.25334295v1.26","doi-asserted-by":"publisher","DOI":"10.2307\/2290910"},{"key":"2025083000350614000_2025.08.23.25334295v1.27","unstructured":"Fox, J. and S. Weisberg , Cox proportional-hazards regression for survival data. An R and S-PLUS companion to applied regression, 2002. 2002."},{"key":"2025083000350614000_2025.08.23.25334295v1.28","doi-asserted-by":"crossref","unstructured":"Hertz-Picciotto, I. and B. Rockhill , Validity and efficiency of approximation methods for tied survival times in Cox regression. Biometrics, 1997: p. 1151\u20131156.","DOI":"10.2307\/2533573"},{"issue":"1","key":"2025083000350614000_2025.08.23.25334295v1.29","doi-asserted-by":"crossref","first-page":"58","DOI":"10.18553\/jmcp.2022.28.1.58","article-title":"Application of a diazepam milligram equivalency algorithm to assess benzodiazepine dose intensity in Rhode Island in 2018","volume":"28","year":"2022","journal-title":"Journal of Managed Care & Specialty Pharmacy"},{"key":"2025083000350614000_2025.08.23.25334295v1.30","doi-asserted-by":"crossref","unstructured":"Corroon Jr, J.M. , L.K. Mischley , and M. Sexton , Cannabis as a substitute for prescription drugs\u2013a cross-sectional study. Journal of pain research, 2017: p. 989\u2013998.","DOI":"10.2147\/JPR.S134330"},{"issue":"3","key":"2025083000350614000_2025.08.23.25334295v1.31","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1089\/can.2018.0020","article-title":"Reduction of benzodiazepine use in patients prescribed medical cannabis","volume":"4","year":"2019","journal-title":"Cannabis and Cannabinoid Research"},{"issue":"14","key":"2025083000350614000_2025.08.23.25334295v1.32","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1017\/S0033291719002460","article-title":"Characterising heterogeneity in the use of different cannabis products: latent class analysis with 55 000 people who use cannabis and associations with severity of cannabis dependence","volume":"50","year":"2020","journal-title":"Psychological medicine"},{"key":"2025083000350614000_2025.08.23.25334295v1.33","doi-asserted-by":"crossref","unstructured":"Connor, J.P. , et al., Cannabis use and cannabis use disorder. Nature Reviews Disease Primers, 2021. 7(1).","DOI":"10.1038\/s41572-021-00256-3"},{"issue":"5","key":"2025083000350614000_2025.08.23.25334295v1.34","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.amjcard.2017.11.044","article-title":"Residual confounding prohibits interpretation of results after propensity score matching","volume":"121","year":"2018","journal-title":"The American Journal of Cardiology"},{"issue":"4","key":"2025083000350614000_2025.08.23.25334295v1.35","doi-asserted-by":"crossref","first-page":"398","DOI":"10.4997\/jrcpe.2020.409","article-title":"Retrospective studies\u2013utility and caveats","volume":"50","year":"2020","journal-title":"Journal of the Royal College of Physicians of Edinburgh"},{"key":"2025083000350614000_2025.08.23.25334295v1.36","unstructured":"Piumatti, K. , The Therapeutic Potential of Cannabis Compared to Benzodiazepines in the Treatment of Anxiety. 2019, Alliant International University."}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/2025.08.23.25334295","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T20:44:08Z","timestamp":1768509848000},"score":1,"resource":{"primary":{"URL":"http:\/\/medrxiv.org\/lookup\/doi\/10.1101\/2025.08.23.25334295"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,26]]},"references-count":36,"URL":"https:\/\/doi.org\/10.1101\/2025.08.23.25334295","relation":{},"subject":[],"published":{"date-parts":[[2025,8,26]]},"subtype":"preprint"}}